MX2009004696A - Uso de 3-alfa-androestandiol, opcionalmente en combinacion con un inhibidor pde5, en el tratamiento de disfuncion sexual. - Google Patents

Uso de 3-alfa-androestandiol, opcionalmente en combinacion con un inhibidor pde5, en el tratamiento de disfuncion sexual.

Info

Publication number
MX2009004696A
MX2009004696A MX2009004696A MX2009004696A MX2009004696A MX 2009004696 A MX2009004696 A MX 2009004696A MX 2009004696 A MX2009004696 A MX 2009004696A MX 2009004696 A MX2009004696 A MX 2009004696A MX 2009004696 A MX2009004696 A MX 2009004696A
Authority
MX
Mexico
Prior art keywords
androstanediol
alpha
combination
sexual dysfunction
optionally
Prior art date
Application number
MX2009004696A
Other languages
English (en)
Inventor
Jan Johan Adriaan Tuiten
Johannes Martinus Maria Bloemers
Robertus Petrus Johannes Lange
Original Assignee
Emotional Brain Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emotional Brain Bv filed Critical Emotional Brain Bv
Publication of MX2009004696A publication Critical patent/MX2009004696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere al campo de la disfunción sexual masculina y/o femenina. La invención específicamente se refiere al uso de 3-alfa-androestandiol, preferiblemente en combinación con un inhibidor de fosfodiesterasa de tipo 5 (PDE5).
MX2009004696A 2006-11-03 2007-11-02 Uso de 3-alfa-androestandiol, opcionalmente en combinacion con un inhibidor pde5, en el tratamiento de disfuncion sexual. MX2009004696A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06076976A EP1925307A1 (en) 2006-11-03 2006-11-03 Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
PCT/NL2007/050534 WO2008054214A2 (en) 2006-11-03 2007-11-02 Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
MX2009004696A true MX2009004696A (es) 2009-06-05

Family

ID=37846101

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2009004696A MX2009004696A (es) 2006-11-03 2007-11-02 Uso de 3-alfa-androestandiol, opcionalmente en combinacion con un inhibidor pde5, en el tratamiento de disfuncion sexual.
MX2009004693A MX2009004693A (es) 2006-11-03 2007-11-02 Uso de testosterona y una agonista 5-ht1a en el tratamiento de disfunsion sexual.
MX2009004695A MX2009004695A (es) 2006-11-03 2007-11-02 Uso de 3-alfa-androestandiol, opcionalmente en combinacion con un agonista ht1a, en el tratamiento de disfuncion sexual.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2009004693A MX2009004693A (es) 2006-11-03 2007-11-02 Uso de testosterona y una agonista 5-ht1a en el tratamiento de disfunsion sexual.
MX2009004695A MX2009004695A (es) 2006-11-03 2007-11-02 Uso de 3-alfa-androestandiol, opcionalmente en combinacion con un agonista ht1a, en el tratamiento de disfuncion sexual.

Country Status (28)

Country Link
US (10) US8653051B2 (es)
EP (5) EP1925307A1 (es)
JP (8) JP2010509211A (es)
KR (6) KR101796887B1 (es)
CN (6) CN104524580A (es)
AU (3) AU2007314735B2 (es)
BR (3) BRPI0718396A2 (es)
CA (3) CA2668320C (es)
CY (1) CY1117191T1 (es)
DK (1) DK2086544T3 (es)
ES (1) ES2561946T3 (es)
HK (1) HK1135038A1 (es)
HR (1) HRP20160108T1 (es)
HU (1) HUE026752T2 (es)
IL (5) IL198461A (es)
ME (1) ME02410B (es)
MX (3) MX2009004696A (es)
NO (3) NO343597B1 (es)
NZ (3) NZ577392A (es)
PH (2) PH12014501440A1 (es)
PL (1) PL2086544T3 (es)
PT (1) PT2086544E (es)
RS (1) RS54541B1 (es)
RU (4) RU2463054C2 (es)
SI (1) SI2086544T1 (es)
UA (4) UA103592C2 (es)
WO (3) WO2008054215A2 (es)
ZA (3) ZA200903836B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1750766E (pt) 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
AU2012256501B2 (en) * 2011-05-13 2017-04-06 Eb Ip Hybritabs B.V. Drug delivery system
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5828923B2 (ja) 2014-01-30 2015-12-09 国立大学法人高知大学 ニッケル粉の製造方法
WO2015125650A1 (ja) 2014-02-21 2015-08-27 国立大学法人高知大学 ニッケル粉の製造方法
JP6406613B2 (ja) 2014-04-15 2018-10-17 住友金属鉱山株式会社 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法
CN103947533B (zh) * 2014-05-15 2015-12-16 青岛理工大学 生长环境可控的磁化水工厂化豆芽菜生产系统
RU2600845C2 (ru) 2014-07-04 2016-10-27 Общество С Ограниченной Ответственностью "Консорциум-Пик" Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251436A (en) * 1965-03-16 1966-05-17 Dayton Steel Foundry Co Spot-type disk brake
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
DK169601B1 (da) 1983-10-17 1994-12-19 Duphar Int Res Piperazinderivater og farmaceutisk præparat indeholdende et sådant derivat, samt piperazinderivater med mellemproduktanvendelse
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
RU2152787C2 (ru) 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
US6174890B1 (en) 1994-06-02 2001-01-16 Dan Riga Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
CA2189355A1 (en) 1995-03-01 1996-09-06 Yasuo Onoda Imidazoquinazoline derivatives
TR199700930T2 (xx) 1995-03-14 1998-07-21 Vivus Incorporated Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit.
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
WO1996036339A2 (en) 1995-05-15 1996-11-21 Beth Israel Hospital Use of dihydrotestosterone compounds for treating male sexual dysfunction
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
EP0998274B1 (en) * 1997-06-23 2006-01-18 Cellegy Pharmaceuticals, Inc Microdose therapy of vascular conditions by no donors
EP1027057A4 (en) * 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6246436B1 (en) * 1997-11-03 2001-06-12 Agilent Technologies, Inc Adjustable gain active pixel sensor
TW542719B (en) 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
JP2002543128A (ja) 1999-04-30 2002-12-17 リリー アイコス リミテッド ライアビリティ カンパニー 雌性覚醒障害の処置
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US6632419B2 (en) * 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
EP1207902A2 (de) 1999-06-17 2002-05-29 Pharmacia AB VERWENDUNG VON WACHSTUMSHORMON (hGH) ZUR THERAPIE SEXUELLER FUNKTIONSSTÖRUNGEN
RU2180591C2 (ru) * 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
DE10016548A1 (de) 2000-04-03 2001-10-11 Bayer Ag Polyurethan-Dispersionen
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6242436B1 (en) * 2000-06-15 2001-06-05 William Charles Llewellyn Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
JP2004524267A (ja) * 2000-08-30 2004-08-12 ユニメッド・ファーマシューティカルズ・インコーポレーテッド 男性の勃起障害の治療方法、及び性衝動の増強方法
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
ATE361060T1 (de) 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
JP2004522720A (ja) * 2000-12-15 2004-07-29 ファイザー・インク 雄性性的機能障害の処置
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
KR20040052489A (ko) 2001-03-06 2004-06-23 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
EE200300469A (et) 2001-03-28 2004-02-16 Pfizer Inc. N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
JP2007516949A (ja) * 2003-07-16 2007-06-28 ファイザー・インク 性機能不全の治療
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
DE60303854T2 (de) * 2003-11-11 2006-08-10 Mattern, Udo Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
WO2005094827A1 (en) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
BRPI0510074A (pt) 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
PT1750766E (pt) 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
US20070154533A1 (en) * 2005-04-13 2007-07-05 Dudley Robert E Method of increasing testosterone and related steriod concentrations in women
WO2006127057A1 (en) 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
WO2007054791A2 (en) * 2005-11-08 2007-05-18 L'oréal Androgen glucuronides as markers of androgenic activity
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
JP5391204B2 (ja) 2007-11-28 2014-01-15 ウーツェーベー ファルマ ゲーエムベーハー ロチゴチンの多形体

Also Published As

Publication number Publication date
JP2014001235A (ja) 2014-01-09
UA115647C2 (uk) 2017-12-11
NO20092145L (no) 2009-07-21
BRPI0717856A2 (pt) 2013-10-29
US20160082018A1 (en) 2016-03-24
AU2007314735A1 (en) 2008-05-08
CA2668320A1 (en) 2008-05-08
RU2009120990A (ru) 2010-12-10
CN101563086B (zh) 2013-11-27
IL248563B (en) 2018-11-29
PT2086544E (pt) 2016-03-17
EP2937086A1 (en) 2015-10-28
ZA200903836B (en) 2010-08-25
AU2007314736B2 (en) 2014-01-23
RS54541B1 (en) 2016-06-30
IL198459A (en) 2016-11-30
EP2086544A2 (en) 2009-08-12
JP2010509212A (ja) 2010-03-25
EP2086545A2 (en) 2009-08-12
PL2086544T3 (pl) 2016-07-29
CY1117191T1 (el) 2017-04-05
JP2015157849A (ja) 2015-09-03
PH12014501821B1 (en) 2016-02-01
KR101796887B1 (ko) 2017-11-10
UA103592C2 (uk) 2013-11-11
US9211334B2 (en) 2015-12-15
PH12014501821A1 (en) 2016-02-01
KR20160124246A (ko) 2016-10-26
PH12014501440A1 (en) 2016-02-01
JP5748238B2 (ja) 2015-07-15
NO343597B1 (no) 2019-04-08
MX2009004695A (es) 2009-06-05
HUE026752T2 (en) 2016-07-28
US20120277200A1 (en) 2012-11-01
US8653051B2 (en) 2014-02-18
UA100119C2 (uk) 2012-11-26
US9597335B2 (en) 2017-03-21
CA2668316C (en) 2014-06-10
US10314848B2 (en) 2019-06-11
IL198461A (en) 2017-08-31
CN101557812A (zh) 2009-10-14
US8575139B2 (en) 2013-11-05
ES2561946T3 (es) 2016-03-01
CA2668316A1 (en) 2008-05-08
CN101573119A (zh) 2009-11-04
IL198460A0 (en) 2010-02-17
NO20092143L (no) 2009-07-02
US8648060B2 (en) 2014-02-11
AU2007314734A1 (en) 2008-05-08
JP2017132809A (ja) 2017-08-03
EP2086544B1 (en) 2015-12-23
NZ577392A (en) 2012-11-30
JP2014055142A (ja) 2014-03-27
EP2086548A2 (en) 2009-08-12
US20190262359A1 (en) 2019-08-29
AU2007314736A1 (en) 2008-05-08
CN103381270A (zh) 2013-11-06
JP2014111608A (ja) 2014-06-19
CA2668320C (en) 2014-06-10
IL198459A0 (en) 2010-02-17
DK2086544T3 (en) 2016-02-08
AU2007314735B2 (en) 2014-01-16
RU2646447C2 (ru) 2018-03-05
KR20150038251A (ko) 2015-04-08
KR20090115113A (ko) 2009-11-04
CN103599536A (zh) 2014-02-26
RU2464027C2 (ru) 2012-10-20
KR20090111803A (ko) 2009-10-27
CN104524580A (zh) 2015-04-22
ME02410B (me) 2016-09-20
UA101948C2 (uk) 2013-05-27
NO20092146L (no) 2009-07-21
WO2008054214A3 (en) 2009-04-09
KR20150099620A (ko) 2015-08-31
CN101563086A (zh) 2009-10-21
AU2007314734B2 (en) 2014-01-30
WO2008054215A2 (en) 2008-05-08
JP2010509213A (ja) 2010-03-25
HRP20160108T1 (hr) 2016-03-25
EP1925307A1 (en) 2008-05-28
JP2010509211A (ja) 2010-03-25
KR101578224B1 (ko) 2015-12-16
CA2668317A1 (en) 2008-05-08
US20100152145A1 (en) 2010-06-17
ZA200903835B (en) 2010-10-27
US20140038929A1 (en) 2014-02-06
IL198461A0 (en) 2010-02-17
US20100093680A1 (en) 2010-04-15
BRPI0717963A2 (pt) 2013-11-05
WO2008054213A3 (en) 2009-04-09
RU2009120992A (ru) 2010-12-10
RU2463054C2 (ru) 2012-10-10
NZ577390A (en) 2012-12-21
RU2012125827A (ru) 2013-12-27
IL237786A0 (en) 2015-05-31
BRPI0718396A2 (pt) 2013-11-26
RU2009120988A (ru) 2010-12-10
WO2008054213A2 (en) 2008-05-08
US20100160270A1 (en) 2010-06-24
ZA200903837B (en) 2010-08-25
US20140121190A1 (en) 2014-05-01
HK1135038A1 (en) 2010-05-28
US8669242B2 (en) 2014-03-11
WO2008054214A2 (en) 2008-05-08
IL248563A0 (en) 2016-12-29
IL198460A (en) 2016-11-30
JP6357131B2 (ja) 2018-07-11
RU2491073C2 (ru) 2013-08-27
US20140121189A1 (en) 2014-05-01
KR20090111802A (ko) 2009-10-27
SI2086544T1 (sl) 2016-04-29
WO2008054215A3 (en) 2009-04-09
MX2009004693A (es) 2009-06-05
CA2668317C (en) 2016-02-09
US20170157142A1 (en) 2017-06-08
NZ577393A (en) 2012-11-30

Similar Documents

Publication Publication Date Title
MX2009004696A (es) Uso de 3-alfa-androestandiol, opcionalmente en combinacion con un inhibidor pde5, en el tratamiento de disfuncion sexual.
WO2002003995A3 (en) Treatment of male sexual dysfunction
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
EP1740183B8 (en) Novel use for pde5 inhibitors
LT1965802T (lt) Farmaciniai deriniai, apimantys testosteroną ir tadalafilą, skirti panaudoti moterų lytinės disfunkcijos gydymui
TW200631584A (en) A medicament related to mirtazapine for the treatment of hot flush
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
IL166273A0 (en) Methods of treatment of male erectile dysfunction
WO2005013946A3 (en) Methods of treatment inflammatory bowel with lxr agonists
CA113510S (en) Wheel grip
CA118787S (en) Handle
CA117204S (en) Iron
CA114756S (en) Faucet
CA120494S (en) Sling shot
AU308951S (en) Tap handle
AU311277S (en) Hammer
CA114777S (en) Handle
CA118270S (en) Wrench set case
CA111219S (en) Wrench set case
AU310572S (en) Engine
CA113832S (en) Coffee sleeve
TW200608951A (en) Hygienic slipcover for male
CA114672S (en) Faucet set
AU310567S (en) Gear knob
CA119038S (en) Can end

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EB IP LYBRIDO B.V.

FC Refusal